Medtronic plc

Equities

MDT

IE00BTN1Y115

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:02 2024-04-19 pm EDT			5-day change	1st Jan Change
79.48 ^USD	+0.37%		-0.81%	-3.52%

Apr. 17	Baird Adjusts Medtronic Price Target to $88 From $91	MT
Apr. 15	Integer Holdings to Benefit from Pulsed Field Ablation Market Growth, BofA Says	MT

Medtronic Sees 9 Percent Organic Revenue Growth in Fiscal 2022

May 27, 2021 at 07:27 am EDT

By Matt Grossman

Medtronic PLC said Thursday that it estimates organic sales growth will drive a higher adjusted profit in the coming fiscal year.

The Ireland-based medical-technology company forecast organic revenue growth of 9%, compared with full-year revenue of $30.12 billion in fiscal 2021. It forecast adjusted earnings of $5.60 to $5.75 a share.

Analysts surveyed by FactSet were anticipating fiscal 2022 revenue of $32.67 billion and adjusted earnings of $5.75 a share.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

05-27-21 0726ET

Latest news about Medtronic plc

Baird Adjusts Medtronic Price Target to $88 From $91	Apr. 17	MT
Integer Holdings to Benefit from Pulsed Field Ablation Market Growth, BofA Says	Apr. 15	MT
Penumbra, Inc. : The underdog in healthcare	Apr. 11
Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO	Apr. 10	CI
Medtronic plc Announces Collaboration with Modernizing Medicine	Apr. 10	CI
ModMed & Medtronic Collaborate to Drive Efficiencies in Documenting Colonoscopies Using AI	Apr. 10	CI
Conflicting signals on rate cuts	Apr. 09
ANALYST RECOMMENDATIONS : Amex, Cisco, Nasdaq, Wells Fargo, Marathon Petroleum...	Apr. 09
Transcript : Medtronic plc - Shareholder/Analyst Call	Apr. 07
Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut? Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women	Apr. 07	CI
Titan Medical Reports Fiscal Year 2023 Results	Apr. 01	MT
Medtronic Says FDA Approved Transcatheter Aortic Valve Replacement System for Heart Valve Disease	Mar. 27	MT
Axonics to File for Review After Patent Board Invalidates Claims in Medtronic Case	Mar. 21	MT
Medtronic to Ask Court to Resume Patent Infringement Case Against Axonics After Favorable Patent Office Ruling	Mar. 21	MT
Transcript : Medtronic plc Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 08:00 AM	Mar. 12
Advance Auto Parts to add three board members as activist investors take stake	Mar. 11	RE
Advance Auto Parts Has Cooperation Accord With Activist Investors Third Point, Saddle Point; Three Directors Named	Mar. 11	MT
Medtronic plc Presents New Clinical and Real-World Data on the MiniMed? 780G System from Around the World	Mar. 09	CI
Medtronic Board Authorizes Incremental $5 Billion for Buybacks; $1.9 Billion Remains Under March 2019 Repurchase Program	Mar. 07	MT
Medtronic Keeps Fiscal Q4 Cash Dividend at $0.69 a Share, Payable April 12 to Holders of Record March 22	Mar. 07	MT
Medtronic plc Approves Cash Dividend for the Fourth Quarter of Fiscal Year 2024, Payable on April 12, 2024	Mar. 07	CI
Medtronic plc announces an Increase in Equity Buyback.	Mar. 06	CI
Tranche Update on Medtronic plc's Equity Buyback Plan announced on June 23, 2017.	Feb. 27	CI
UBS Raises Medtronic Price Target to $75 From $72, Maintains Sell Rating	Feb. 21	MT
Deutsche Bank Adjusts Medtronic Price Target to $85 From $79, Maintains Hold Rating	Feb. 21	MT

Chart Medtronic plc

Duration

Period

More charts

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-23 - Q4 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Medtronic plc : Still struggling to convince

November 24, 2023 at 08:21 am EST

More Strategies

Ratings for Medtronic plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

79.48 USD

Average target price

94.75 USD

Spread / Average Target

+19.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
MEDTRONIC PLC	-3.52%	105B
ABBOTT LABORATORIES	-2.53%	183B
DEXCOM, INC.	+5.33%	51.77B
CENCORA, INC.	+16.43%	47.29B
HOYA CORPORATION	-1.73%	40.2B
WEST PHARMACEUTICAL SERVICES, INC.	+5.66%	27.62B
METTLER-TOLEDO INTERNATIONAL, INC.	-2.01%	25.51B
TERUMO CORPORATION	+9.84%	24.73B
ZIMMER BIOMET HOLDINGS, INC.	-1.87%	24.52B
ALIGN TECHNOLOGY, INC.	+9.12%	22.68B

Other Medical Equipment, Supplies & Distribution